NCT05217537View on ClinicalTrials.gov

Study to Evaluate the PK of IV and PO Omadacycline in Children and Adolescents With Suspected or Confirmed Bacterial Infections

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 6, 2022

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions
Bacterial Infections
Interventions
DRUG

Omadacycline Injection [Nuzyra]

Single dose of 100 mg omadacycline IV in 100 mL of normal saline

DRUG

Omadacycline Oral Tablet

Single dose of 300 mg omadacycline PO (2 x 150 mg tablets)

Trial Locations (9)

19104

RECRUITING

Site 113, Philadelphia

27858

RECRUITING

Site 111, Greenville

60611

RECRUITING

Site 105, Chicago

RECRUITING

Site 106, Cleveland

72202

RECRUITING

Site 109, Little Rock

77030

RECRUITING

Site 108, Houston

80045

RECRUITING

Site 114, Aurora

90806

RECRUITING

Site 112, Long Beach

92868

RECRUITING

Site 107, Orange

Sponsors
All Listed Sponsors
lead

Paratek Pharmaceuticals Inc

INDUSTRY